Mounjaro 15mg KwikPen

Mounjaro 15mg KwikPen contains Tirzepatide, a dual GIP and GLP-1 receptor agonist used for type 2 diabetes management. It is taken once a week and helps with weight loss and blood sugar control.

Brand Name: Mounjaro

Composition: Tirzepatide

Mechanism of Action:

A dual GIP and GLP-1 receptor agonist, tirzepatide aids in controlling blood sugar levels in people with type 2 diabetes. It functions by slowing stomach emptying, which raises satiety and may aid in weight loss, decreasing glucagon levels to lower blood sugar, and increasing insulin production in response to meal consumption.

Uses:

·       Type-2 Diabetes Mellitus

·       Weight Management

Dosage and Administration:

·       The recommended dosage is 15 mg once weekly subcutaneously (abdomen, thigh, or upper arm, rotating sites).

·       After taking 12.5 mg once weekly for at least four weeks, this dosage is used.

·       For glycemic management, a maximum dose of 15 mg once weekly is advised.

·       It can be taken with or without food, at any time of day; if a dose is missed, it should be taken within four days; otherwise, skip the dose and carry on as usual.

Side Effects:

·       Nausea

·       Vomiting

·       Diarrhea

·       Constipation

·       Decreased appetite

·       Injection site reactions (Itching, Rashes)

·       Hypoglycemia

Safety Advise:

Lungs  

The safety of Mounjaro for individuals with lung issues is uncertain. Kindly speak with your healthcare provider.

Liver  

The safety of Mounjaro for individuals with liver issues is uncertain. Kindly speak with your healthcare provider.

Kidney  

The safety of Mounjaro for individuals with Kidney issues is uncertain. Kindly speak with your healthcare provider.

Pregnancy  

Mounjaro should be used during pregnancy only if clearly needed, Kindly speak with your healthcare provider.

Breast Feeding  

Using Mounjaro while nursing is most likely dangerous. Kindly speak with your healthcare provider. 

Storage:

Avoid freezing the Mounjaro KwikPen and keep it in a refrigerator between 2°C and 8°C. After usage, it can be stored for 21 days at room temperature (up to 30°C) under protection from heat and light.

How to use this Medication?

This drug is administered subcutaneously. You'll learn how to prepare and administer it. It is administered once every seven days, or once a week. Unless instructed otherwise by your healthcare provider, continue taking it.

You should inject this medication and insulin separately if you take both together. Don't combine them. Avoid administering the shots directly close to one another. With every injection, rotate the injection sites.

References:

1.   Baker DE, Walley K, Levien TL. Tirzepatide. Hospital Pharmacy. 2023 Jun;58(3):227-43.

2.  Karagiannis T, Avgerinos I, Liakos A, Del Prato S, Matthews DR, Tsapas A, Bekiari E. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia. 2022 Aug;65(8):1251-61.

3.  Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022 Jul 21;387(3):205-16.

4.  Chavda VP, Ajabiya J, Teli D, Bojarska J, Apostolopoulos V. Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: a mini-review. Molecules. 2022 Jul 5;27(13):4315.

Disclaimer:

The main goal of Apothecare Wellness is to make sure that the information it provides to customers is correct, reliable, and reviewed by specialists. This website's contents and information are strictly for informational purposes. They are not meant to be used in place of expert medical advice, diagnosis, or care. Please consult your physician for guidance and ask any questions you may have about any condition or medication. If you read anything on Apothecare Wellness, do not discount or delay obtaining competent medical advice. Our goal is to enhance the doctor-patient relationship, not to take its place.

Marketer details

Name: Eli Lilly and Company India Pvt Ltd

Address: Plot# 92, Sector 32, Institutional Area, Gurgaon-122001, HARYANA, INDIA

Country of origin: United states

Frequently Asked Questions:

1. What is Mounjaro 15mg KwikPen?
Mounjaro 15mg KwikPen contains the highest available maintenance dose of Tirzepatide. It may be considered for patients with Type 2 diabetes who require additional blood sugar control and who have demonstrated adequate tolerance of progressively lower doses during the titration process.

2. When is the 15mg dose typically considered?
The 15mg dose is generally the final step in the Tirzepatide titration schedule (2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg), reached over several months. It is only considered when lower doses are well tolerated and additional glycaemic benefit is needed, as determined by your physician.

3. May the 15mg dose offer additional clinical benefits over lower doses?
Some clinical data suggest that the 15mg dose may be associated with greater reductions in HbA1c and more pronounced weight changes compared to lower doses in some patients. However, individual responses vary and higher doses may also carry a greater risk of side effects. Your doctor will determine the most appropriate dose for your needs.

4. How is Mounjaro 15mg KwikPen administered?
It is intended to be injected subcutaneously once weekly. Injection sites should be rotated (abdomen, thigh, or upper arm) to help reduce localised skin reactions.

5. What are the possible side effects at the 15mg dose?
Side effects are generally similar to lower doses but may be more frequently reported at higher doses:
•         Nausea
•         Vomiting
•         Diarrhoea
•         Constipation
•         Abdominal pain
These may lessen over time with continued use, though not in all patients. Please consult your doctor if they are significantly affecting your quality of life.

6. Is the 15mg dose appropriate for all patients?
Not all patients will require or tolerate the 15mg dose. It should only be prescribed by a doctor who has reviewed the patient's clinical response, tolerability, and ongoing need for dose escalation.

7. Can the dose be temporarily reduced if side effects occur?
In some cases, a physician may consider reducing the dose temporarily if side effects are intolerable, with a possible attempt at re-escalation when clinically appropriate. Dose adjustments should never be made without consulting your doctor.

8. Does Mounjaro 15mg work differently from lower doses?
The mechanism of action is the same across all doses. Higher doses provide a stronger pharmacological effect through more complete activation of GIP and GLP-1 receptors, which may translate to greater clinical benefits in some patients.

9. How should Mounjaro 15mg be stored?
Store in a refrigerator at 2°C–8°C. It may be kept at room temperature (up to 30°C) for up to 21 days once in use. Do not freeze or expose to direct sunlight. Refer to the product label for full storage instructions.

10. Is Mounjaro 15mg a prescription medicine?
Yes. All Mounjaro doses, including the 15mg KwikPen, are prescription-only medicines that must be used under the supervision of a qualified physician.

Medical Disclaimer:
Mounjaro 15mg KwikPen is a prescription-only medicine and must be used strictly under the supervision and guidance of a qualified healthcare professional. Do not self-medicate, alter the dosage, or discontinue use without consulting your doctor. The information provided here is for educational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment. Individual results, benefits, and risks may vary. Always consult your physician before starting, changing, or stopping any medication.